Progyny (NASDAQ:PGNY) Issues Earnings Results, Misses Estimates By $0.28 EPS

Progyny (NASDAQ:PGNY) issued its quarterly earnings data on Thursday. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.36 by ($0.28), Zacks reports. Progyny had a return on equity of 11.36% and a net margin of 5.03%. Progyny updated its Q1 2025 guidance to 0.440-0.470 EPS and its FY 2025 guidance to 1.520-1.620 EPS.

Progyny Stock Performance

NASDAQ PGNY traded down $0.12 on Thursday, reaching $22.88. The stock had a trading volume of 2,436,975 shares, compared to its average volume of 1,794,328. The stock has a market cap of $1.95 billion, a P/E ratio of 39.45, a price-to-earnings-growth ratio of 2.39 and a beta of 1.34. The business’s 50-day moving average price is $20.34 and its 200 day moving average price is $18.65. Progyny has a 12-month low of $13.39 and a 12-month high of $38.98.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PGNY shares. Barclays cut their price objective on Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Bank of America raised their price objective on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Canaccord Genuity Group dropped their target price on shares of Progyny from $18.00 to $17.00 and set a “hold” rating for the company in a report on Wednesday, November 13th. JPMorgan Chase & Co. increased their target price on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. Finally, Truist Financial reissued a “hold” rating and issued a $19.00 target price (down previously from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $25.83.

Insider Activity

In other news, Chairman David J. Schlanger acquired 150,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were purchased at an average cost of $14.68 per share, for a total transaction of $2,202,000.00. Following the transaction, the chairman now directly owns 228,269 shares in the company, valued at approximately $3,350,988.92. This represents a 191.65 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Peter Anevski acquired 209,500 shares of the business’s stock in a transaction on Monday, December 23rd. The shares were purchased at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the transaction, the chief executive officer now owns 441,463 shares in the company, valued at $6,392,384.24. The trade was a 90.32 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 12.30% of the company’s stock.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.